Javascript er ikke aktivert i din nettleser. Dette er nødvendig for å bruke Oncolex. Kontakt din systemadministrator for å aktivere JavaScript.

Prognosis of ovarian and fallopian tube cancer

Ovarian cancer

The prognosis depends on whether the ovarian cancer is localized, regional, or metastatic at the time of diagnosis. For ovarian cancer, 14.8% are diagnosed at the local stage and the 5-year survival for localized ovarian cancer is 92.5%. The overall 5-year survival rate for ovarian cancer patients during the period 2007-2013 was 46.5%.

The percent of ovarian cancer deaths is highest among women aged 65-74. Death rates have been falling on average 2.2% each year over 2005-2014.

In 2014, there were an estimated 222,060  women living with ovarian cancer in the United States and in 2017 there are an estimated 14,080 women will die of this disease (23).

Ploidy analysis

Multiple biological prognostic factors are correlated with prognosis of epithelial cancer types. Oslo University Hospital (The Norwegian Radium Hospital) has shown that epithelial ovarian cancers are often aneuploid. They have also shown a high correlation between FIGO stage and ploidy. That is, early early stage ovarian cancer has a tendency towards diploid and advanced tumors have a tendency to be aneuploid. Patients with diploid tumors have a significantly longer median survival time than those with aneuploid tumors, which are five and one year(s) respectively. Multivariant analyses have shown that ploidy is an independent prognostic factor.

 

Survival in 321 patients with ovarial border-line tumors related to ploidy and stage.

 

In vitro clonogenic assay

A significant inverse correlation has been reported between clonogenic growth in vitro and survival. Multivariant analysis has found that clonogenic growth in a semisolid culture medium is a significant independent variable. The prediction model "extreme drug resistance assay" has suggested that it is possible to decide chemotherapy by evaluating platinum-sensitive and resistant tumors in vitro. This technique is used at the department for gynecological cancer at Oslo University Hospital (The Norwegian Radium Hospital). It is still unknown whether this method alone can predict or change the outcome of a primary or recurrence situation.

Oslo University Hospital shall not be liable for any loss whether direct, indirect, incidental or consequential, arising out of access to, use of, or reliance upon any of the content on this website. Oslo University Hospital© 2017